| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/01/2006 | CN1726938A Hygienical coating lotion for treating diabetic feet, preparation method and application |
| 02/01/2006 | CN1726934A Medication combination of Xuefu Zhuyu in application for preparing hypolipidemic |
| 02/01/2006 | CN1726929A Compsn. of medication for treating diabetes |
| 02/01/2006 | CN1726921A Oral preparation of prostaglandin E1 |
| 02/01/2006 | CN1726920A Nose taking powder of prostaglandin E |
| 02/01/2006 | CN1726916A Oral disintegration tablet for dropping blood sugar and preparation method |
| 02/01/2006 | CN1726912A Slow release capsule of compound metformin pyrrolidone and preparation method |
| 02/01/2006 | CN1726907A Method of preparing medication for preventing and curing hyperlipoidemia by using flavones picking up from marc of blueberry |
| 02/01/2006 | CN1239501C A thiazolidniedione derivative and its use as antidiabetic |
| 02/01/2006 | CN1239196C Nutrient healthy powder for decreasing blood sugar and resolving stagnation |
| 02/01/2006 | CN1239195C Compound flavone capsule and pellet prepn. method |
| 02/01/2006 | CN1239186C Soft hypolipidemic Jiaosuan capsule and its production process |
| 02/01/2006 | CN1239183C A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof |
| 02/01/2006 | CN1239182C Chinese traditional medicine composition for treating cerebral infarction and hyperlipoidemia |
| 02/01/2006 | CN1239179C Chinese medicine for treating diabetes and preparation method therefor |
| 02/01/2006 | CN1239166C Hypoglycemic biopreparation |
| 02/01/2006 | CN1239160C Hormone replacement therapy |
| 02/01/2006 | CN1239159C Medicine composition for reducing blood fat |
| 02/01/2006 | CN1239156C Oral Solution for preventing and treating acalcerosis and its prepn process |
| 02/01/2006 | CN1239154C 5-HT IA receptor subtype agonist |
| 02/01/2006 | CN1239150C Nano grade vitamin micro emulsion and its preparing method |
| 01/31/2006 | US6992194 suspending crystal strutured or amorphous lipitor in diluents comprising alcohols and/or water mixtures to cause conversion, then separating the diluents; monodispersity |
| 01/31/2006 | US6992171 Polypeptide and its DNA |
| 01/31/2006 | US6992094 selenium nicotinic acid tetrahyronaphthaline compounds; treating skin disorders |
| 01/31/2006 | US6992085 Octahydro-2H-pyrido[1,2-a]pyrazine compounds |
| 01/31/2006 | US6992084 Compounds and methods for modulating CXCR3 function |
| 01/31/2006 | US6992074 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/31/2006 | US6992067 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use |
| 01/31/2006 | US6992060 Short term treatment with composition having gastrin/cholecystokinin receptor ligand and EGF receptor ligand, resulting in prolonged period of increased insulin release |
| 01/31/2006 | US6991908 Antiobestic agents methods for screening antiobestic agents and kits comprising same |
| 01/31/2006 | US6991901 Administering an antibody to the polypeptide sec1; angiogenesis inhibitors |
| 01/31/2006 | CA2327498C Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
| 01/31/2006 | CA2314154C Azepine or larger medium ring derivatives and their use as pharmaceuticals |
| 01/26/2006 | WO2006009975A2 Histamine to treat disorders affecting muscle function |
| 01/26/2006 | WO2006009464A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/26/2006 | WO2006009092A1 Method of effectively using medicine and method concerning prevention of side effect |
| 01/26/2006 | WO2006008656A2 Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
| 01/26/2006 | US20060020138 E.g., 3-arylmethyl-7-hydroxy-coumarins as intermediates; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/26/2006 | US20060020046 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
| 01/26/2006 | US20060020002 (3a alpha ,4 alpha ,7 alpha ,7a alpha )-Octahydro-3-hydroxy-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one (2); steroid mimic; competitive inhibitors of intercellular ligand binding reactions involving CAMs and Leukointegrins; anticarcinogenic agent; autoimmune diseases |
| 01/26/2006 | US20060019999 Specific inhibitors of one or more isoforms of nitric oxide synthase; 3-[[2-amino-1-phenylethyl]thio]-5-methyl-2-thiophenecarbonitrile; antiinflammatory agent; pain |
| 01/26/2006 | US20060019977 Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient |
| 01/26/2006 | US20060019945 Granzyme b inhibitors |
| 01/26/2006 | US20060019897 Anti-angiogenic polypeptides |
| 01/26/2006 | US20060018983 Composition containing green-yellow vegetables and light-colored vegetables |
| 01/26/2006 | CA2833770A1 Oxidative degradation products of atorvastatin calcium |
| 01/26/2006 | CA2612303A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | CA2574423A1 Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies |
| 01/26/2006 | CA2574381A1 Composition comprising protein material and non-oxidizable fatty acid entities |
| 01/26/2006 | CA2574366A1 Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities |
| 01/26/2006 | CA2574360A1 A preparation for use of aspartate for regulating glucose levels in blood |
| 01/26/2006 | CA2574162A1 Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase 1b (ptp1b) inhibitors for using as blood-sugar decreasing active ingredients for treating diabetes |
| 01/26/2006 | CA2574006A1 Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| 01/26/2006 | CA2572793A1 Progression inhibitor for disease attributed to abnormal accumulation of liver fat |
| 01/25/2006 | EP1619250A1 WSX receptor and ligands |
| 01/25/2006 | EP1619194A2 Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient |
| 01/25/2006 | EP1619193A1 Spiropiperidine compound and medicinal use thereof |
| 01/25/2006 | EP1619192A2 Aryl fused azapolycyclic compounds |
| 01/25/2006 | EP1619180A1 CaSR ANTAGONIST |
| 01/25/2006 | EP1618898A2 Methods for regulating angiogenesis |
| 01/25/2006 | EP1618893A1 Sugar intake-ability enhancer |
| 01/25/2006 | EP1618882A2 Estrogen compositions for neuroprotection |
| 01/25/2006 | EP1618878A1 Body-temperature lowering depressant |
| 01/25/2006 | EP1618801A1 Phaseolamin compositions and methods for using the same |
| 01/25/2006 | EP1618212A1 Mutations in the human pcsk9 gene associated to hypercholesterolemia |
| 01/25/2006 | EP1618112A1 Heterocyclic mchr1 antagonists |
| 01/25/2006 | EP1618105A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders |
| 01/25/2006 | EP1618096A1 11-phenyl-dibenzodiazepine derivatives as rxr-antagonists |
| 01/25/2006 | EP1618090A1 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| 01/25/2006 | EP1618086A2 Compounds for the treatment of metabolic disorders |
| 01/25/2006 | EP1617856A2 Somatostatin-dopamine chimeric analogs |
| 01/25/2006 | EP1617839A1 The use of azetidinecarboxamide derivatives in therapy |
| 01/25/2006 | EP1617835A2 Compounds for the treatment of metabolic disorders |
| 01/25/2006 | EP1617832A1 Compositions for affecting weight loss |
| 01/25/2006 | EP1617724A1 Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| 01/25/2006 | EP1393066A4 Insulin producing cells derived from human embryonic stem cells |
| 01/25/2006 | EP1372627B1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/25/2006 | EP1235825B1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 01/25/2006 | EP1135127B1 New pharmaceutical composition and the process for its preparation |
| 01/25/2006 | EP0914158B2 Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity |
| 01/25/2006 | CN1726213A Imidazoquinoline derivatives as adenosine A3 receptor ligands |
| 01/25/2006 | CN1726210A Novel compounds having selective inhibiting effect at GSK3 |
| 01/25/2006 | CN1726206A Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 01/25/2006 | CN1726197A 5-substituted-pyrazine or -pyridine glucokinase activators |
| 01/25/2006 | CN1726189A Novel MCH receptor antagonists |
| 01/25/2006 | CN1726188A Treating syndrome X with substituted tetralins and indanes |
| 01/25/2006 | CN1726049A Compositions, methods, and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors |
| 01/25/2006 | CN1724563A Exendin 4 polypeptide segment |
| 01/25/2006 | CN1724519A Indole kind compound with insuline sensitizing activity and its preparation method and use |
| 01/25/2006 | CN1724065A Medicine for treating diabetes, and its prepn. method |
| 01/25/2006 | CN1724063A Method for producing turmeric stable prepn. |
| 01/25/2006 | CN1724056A Salmon roe nutrition and health-care soft capsule, and its prepn. process |
| 01/25/2006 | CN1724038A Traditional Chinese herb medicine tea with function of lowering fat and decreasing weight |
| 01/25/2006 | CN1724018A 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method |
| 01/25/2006 | CN1724017A Compound dripping pills contg. fruit of Chinese haw-thorn, and its prepn. method |
| 01/25/2006 | CN1724004A Health-care medicine for treating and preventing complication of diabetes mellitus |
| 01/25/2006 | CN1724002A Medicinal composition, and its pharmaceutical use |
| 01/25/2006 | CN1723962A Application of total flavone of |
| 01/25/2006 | CN1723950A Traditional Chinese medicine for treating hyperlipidemia and its complicating diseases |
| 01/25/2006 | CN1723917A Superfine fresh bone with marrow high calcium powder capsule |